(Q38614104)

4 September 2017

0 references

Oxycodone for cancer-related pain (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

author name string

Mia Schmidt-Hansen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

Stephanie Arnold

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

Nathan Bromham

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

Jennifer S Hilgart

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

publication date

22 August 2017

1 reference

PubMed ID

28829910

full work available at URL

4 September 2017

http://eprints.whiterose.ac.uk/120695

content deliverer

White Rose Research Online

object has role

published version

1 reference

White Rose Research Online

http://eprints.whiterose.ac.uk/120695

Cochrane Database of Systematic Reviews

15 December 2018

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

page(s)

CD003870

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV 'real life' trial on the variability of response to opioids

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Controlled-release oxycodone and morphine in cancer related pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Morphine or oxycodone in cancer pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Efficacy and safety of oral tapentadol extended release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Morphine and oxycodone hydrochloride in the management of cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Morphine and oxycodone in the management of cancer pain: plasma levels determined by chemical and radioreceptor assays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Morphine or oxycodone for cancer-related pain? A randomized, open-label, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate-release oral oxycodone in cancer pain patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Should opioids be used for chronic non-cancer pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Can morphine still be considered to be the standard for treating chronic pain? A systematic review including pair-wise and network meta-analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Controlled clinical trials in cancer pain. How controlled should they be? A qualitative systematic review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Is oral morphine still the first choice opioid for moderate to severe cancer pain? A systematic review within the European Palliative Care Research Collaborative guidelines project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Facial affect processing in patients receiving opioid treatment in palliative care: preferential processing of threat in pain catastrophizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

The dose-response relationship of controlled-release codeine (Codeine Contin) in chronic cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Decreasing use of controlled-release oxycodone: response to Morden et al, June 2008 Medical Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A systematic review of oxycodone in the management of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Effectiveness of topical administration of opioids in palliative care: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Relief of pain by oral medications. A controlled evaluation of analgesic combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Serum concentrations of opioids when comparing two switching strategies to methadone for cancer pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Oxycodone and the challenge of neuropathic cancer pain: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A Systematic Review of Prospective Studies Reporting Adverse Events of Commonly Used Opioids for Cancer-Related Pain: A Call for the Use of Standardized Outcome Measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Validation of the Bowel Function Index to detect clinically meaningful changes in opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Efficacy of oxycodone/paracetamol for patients with bone-cancer pain: a multicenter, randomized, double-blinded, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Analgesic efficacy of zomepirac sodium in patients with pain due to cancer

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

21 January 2018

12 December 2020

Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A randomized double-blind crossover comparison of continuous and intermittent subcutaneous administration of opioid for cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Opioid therapies and cytochrome p450 interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Role of oxycodone and oxycodone/naloxone in cancer pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

A validation study of the WHO method for cancer pain relief

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Opioid prescribing for patients with cancer in the last year of life: a longitudinal population cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Oxycodone for cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003870.PUB6

Intravesical baclofen, bupivacaine, and oxycodone for the relief of bladder spasm.

21 January 2018

1 reference

12 December 2020

Efficacy, tolerability and acceptability of oxycodone for cancer-related pain in adults: an updated Cochrane systematic review.

1 reference

12 December 2020

The use of controlled-release oxycodone for the treatment of chronic cancer pain: a randomized, double-blind study

1 reference

12 December 2020

Double-blind comparisons of zomepirac and oxycodone with APC in cancer pain

1 reference

12 December 2020

Pharmacoeconomics evaluation of morphine, MS contin and oxycodone in the treatment of cancer pain

1 reference

12 December 2020

Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose

1 reference

12 December 2020

Oxycodone frequently induced nausea and vomiting in oxycodone-naïve patients with hepatic dysfunction

1 reference

12 December 2020

The Adverse Events of Oxycodone in Cancer-Related Pain: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

1 reference

12 December 2020

Extended release oxycodone. An oral opioid analgesic for cancer patients with chronic pain

1 reference

12 December 2020

Oxycodone for Cancer Pain in Adult Patients

1 reference

12 December 2020

A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain

1 reference

12 December 2020

Clinical evaluation of the first oxycodone once daily prolonged release tablet in moderate to severe chronic pain: a randomized, double-blind, multicenter, cross-over, non-inferiority study to investigate efficacy and safety in comparison with an es

1 reference

12 December 2020

Efficacy of controlled-release oxycodone

1 reference

12 December 2020

Comparative clinical efficacy and safety of a novel controlled-release oxycodone formulation and controlled-release hydromorphone in the treatment of cancer pain

1 reference

12 December 2020

Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone

1 reference

12 December 2020

Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost-utility analysis

1 reference

12 December 2020

Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of oxycodone when given intravenously and rectally to adult patients with cancer pain

1 reference

12 December 2020

Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain

1 reference

12 December 2020

A systematic review of randomized trials on the effectiveness of opioids for cancer pain

1 reference

12 December 2020

Use of opioids against severe cancer pain

1 reference

12 December 2020

Safety and efficacy of once-daily hydromorphone extended-release versus twice-daily oxycodone hydrochloride controlled-release in chinese patients with cancer pain: a phase 3, randomized, double-blind, multicenter study

1 reference

12 December 2020

Analgesic studies of codeine and oxycodone in patients with cancer. I. Comparisons of oral with intramuscular codeine and of oral with intramuscular oxycodone

1 reference

12 December 2020

Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain

1 reference

12 December 2020

Analgesic studies of codeine and oxycodone in patients with cancer. II. Comparisons of intramuscular oxycodone with intramuscular morphine and codeine

1 reference

12 December 2020

10.1002/14651858.CD003870.PUB6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

10.1002/14651858.CD003870.PUB6

13 May 2020

Altmetric DOI

0 references

Dimensions Publication ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6421939&resulttype=core&format=json